Skip to main content
OpenTrials
Completed

NCT Number: NCT00434577

Safety and Immunogenicity of the Zoster Vaccine GSK1437173A in Elderly Subjects

Based on the results of a previous clinical PhaseI/II study, GSK1437173A is the lead GSK candidate Herpes Zoster (HZ) vaccine to prevent episodes of HZ (shingles). This phase II study will be subdivided into a primary study (108494) and three extension studies (108516, 108518 & 108520), consisting of one additional visit each at months 12, 24 and 36, respectively, from the first visit of the Zoster-003 primary study onwards. The aim of the primary 108494 study is to evaluate the immunogenicity & safety of different dosages of the GSK1437173A vaccine in healthy elderly population. The study population will be stratified by age. The primary objective of this trial is to select the best dosage of GSK1437173A. The aim of the extension studies is to evaluate the persistence of the immune response induced by the candidate HZ vaccine during a long term period.

No new subjects will be enrolled during the extension phases of the study.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Herpes Zoster Chickenpox DNA Virus Infections Herpesviridae Infections Infections Varicella Zoster Virus Infection Virus Diseases

Age range

60 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

GSK Investigational Site, Hradec Králové, Czechia

Loading trial locations.

About this study

The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects who the investigator believes that they can and will comply with the requirements of the protocol.
  • A male or female aged 60 years or older at the time of the first vaccination.
  • Written informed consent obtained from the subject

Exclusion criteria

  • Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first injection with study vaccine, or planned use during the study period.
  • Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs during the study period, except inhaled and topical steroids are allowed.
  • Administration or planned administration of a vaccine not foreseen by the study protocol within 2 weeks of the first study vaccine injection, with the exception of the influenza vaccine, which can be administered 1 week preceding or 1 month after the first study vaccine injection.
  • Previous vaccination against HZ.
  • History of herpes zoster (Shingles).
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
  • Acute disease at the time of enrolment.
  • Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by subject's medical history or physical examination as assessed by the investigator.
  • Administration of immunoglobulins and/or any blood products within the 3 months preceding the first injection of study vaccine or planned administration during the study period.
  • History of or current drug and/or alcohol abuse.

Treatment and study plan

Herpes Zoster vaccine GSK1437173A Low Dose

Biological

Single or two-dose intramuscular injection.

Herpes Zoster vaccine GSK1437173A Medium Dose

Biological

Single or two-dose intramuscular injection.

Herpes Zoster vaccine GSK1437173A High Dose

Biological

Single or two-dose intramuscular injection.

Herpes Zoster vaccine GSK1437173A Modified

Biological

Single or two-dose intramuscular injection.

Placebo

Biological

Single intramuscular injection

Primary outcomes

  1. Frequency of Glycoprotein E (gE)-Specific Cluster of Differentiation (CD4) T-cells Expressing at Least Two Different Activation Markers

    Time frame: One month after the second vaccination (Month 3)

    Among the activation markers expressed were interleukin-2 [IL-2] and/or interferon-gamma [IFN-γ] and/or tumour necrosis factor-alpha [TNF-α] and/or cluster of differentiation 40-ligand [CD40-L]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS) in subjects aged 70 or higher (≥).

  2. Frequency Odds Ratio of gE-specific CD4 T-cells Expressing at Least Two Different Activation Markers

    Time frame: One month after the second vaccination (Month 3)

    Among the activation markers expressed were interleukin-2 [IL-2] and/or interferon-gamma [IFN-γ] and/or tumour necrosis factor-alpha [TNF-α] and/or cluster of differentiation 40-ligand [CD40-L]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS) in subjects ≥ 70 years old. The odds-ratios are calculated using the the frequency of CD4 secreting cytokines, upon in vitro stimulation with the specific antigen, at the numerator and the frequency of the CD4 secreting cytokines with the medium only (background level) at the denominator. The odds-ratios represent the fold-change in the specific response compared to the background level.

  3. Frequency of gE-specific CD4 T-cells Expressing at Least Two Different Activation Markers

    Time frame: One month after the second vaccination (Month 3)

    Among the activation markers expressed were interleukin-2 [IL-2] and/or interferon-gamma [IFN-γ] and/or tumour necrosis factor-alpha [TNF-α] and/or cluster of differentiation 40-ligand [CD40-L]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS) in subjects ≥ 70 years old.

Secondary outcomes

  1. Frequency of gE-specific CD4 T-cells Expressing at Least Two Different Activation Markers

    Time frame: At pre-vaccination (Day 0), one month after the first vaccination (Month 2) and second vaccination (Month 3)

    Among the activation markers expressed were interleukin-2 [IL-2] and/or interferon-gamma [IFN-γ] and/or tumour necrosis factor-alpha [TNF-α] and/or cluster of differentiation 40-ligand [CD40-L]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS) in subjects 60 to 69 years (60-69y) and ≥ 70 years (+70y) old.

  2. Frequency of gE-specific CD4 T-cells Expressing IFN-γ and at Least Another Activation Marker

    Time frame: At pre-vaccination (Day 0), one month after the first vaccination (Month 2) and second vaccination (Month 3)

    Among other activation markers expressed were interleukin-2 [IL-2] or tumour necrosis factor-alpha [TNF-α] or cluster of differentiation 40-ligand [CD40-L]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS).

  3. Frequency of gE-specific CD4 T-cells Expressing IL-2 and at Least Another Activation Marker

    Time frame: At pre-vaccination (Day 0), one month after the first vaccination (Month 2) and second vaccination (Month 3)

    Among other activation markers expressed were interferon-gamma [IFN-γ] or tumour necrosis factor-alpha [TNF-α] or cluster of differentiation 40-ligand [CD40-L]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS).

  4. Frequency of gE-specific CD4 T-cells Expressing TNF-α and at Least Another Activation Marker

    Time frame: At pre-vaccination (Day 0), one month after the first vaccination (Month 2) and second vaccination (Month 3)

    Among other activation markers expressed were interleukin-2 [IL-2] or interferon-gamma [IFN-γ] or cluster of differentiation 40-ligand [CD40-L]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS).

  5. Frequency of gE-specific CD4 T-cells Expressing CD40L and at Least Another Activation Marker

    Time frame: At pre-vaccination (Day 0), one month after the first vaccination (Month 2) and second vaccination (Month 3)

    Among other activation markers expressed were interleukin-2 [IL-2] or interferon-gamma [IFN-γ] or tumour necrosis factor-alpha [TNF-α] . Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS).

  6. Frequency of gE-specific CD8 T-cells Expressing at Least Two Different Activation Markers

    Time frame: At pre-vaccination (Day 0), one month after the first vaccination (Month 2) and second vaccination (Month 3)

    Among the activation markers expressed were interleukin-2 [IL-2] and/or interferon-gamma [IFN-γ] and/or tumour necrosis factor-alpha [TNF-α] and/or cluster of differentiation 40-ligand [CD40-L]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS).

  7. Frequency of gE-specific CD8 T-cells Expressing IFN-γ and at Least Another Activation Marker

    Time frame: At pre-vaccination (Day 0), one month after the first vaccination (Month 2) and second vaccination (Month 3)

    Among other activation markers expressed were interleukin-2 [IL-2] or tumour necrosis factor-alpha [TNF-α] or cluster of differentiation 40-ligand [CD40-L]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS).

  8. Frequency of gE-specific CD8 T-cells Expressing IL-2 and at Least Another Activation Marker

    Time frame: At pre-vaccination (Day 0), one month after the first vaccination (Month 2) and second vaccination (Month 3)

    Among other activation markers expressed were interferon-gamma [IFN-γ] or tumour necrosis factor-alpha [TNF-α] or cluster of differentiation 40-ligand [CD40-L]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS).

  9. Frequency of gE-specific CD8 T-cells Expressing TNF-α and at Least Another Activation Marker

    Time frame: At pre-vaccination (Day 0), one month after the first vaccination (Month 2) and second vaccination (Month 3)

    Among other activation markers expressed were interleukin-2 [IL-2] or interferon-gamma [IFN-γ] or cluster of differentiation 40-ligand [CD40-L]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS).

  10. Frequency of gE-specific CD8 T-cells Expressing CD40L and at Least Another Activation Marker

    Time frame: At pre-vaccination (Day 0), one month after the first vaccination (Month 2) and second vaccination (Month 3)

    Among other activation markers expressed were interleukin-2 [IL-2] or interferon-gamma [IFN-γ] or tumour necrosis factor-alpha [TNF-α]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS).

  11. Anti-gE Specific Antibody Concentrations

    Time frame: At pre-vaccination (Day 0), one month after the first vaccination (Month 2) and second vaccination (Month 3)

    Concentrations were presented as geometric mean concentrations (GMCs) and expressed in enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).

  12. Anti-varicella Zoster Virus (VZV) Specific Antibody Concentrations

    Time frame: At pre-vaccination (Day 0), one month after the first vaccination (Month 2) and second vaccination (Month 3)

    Concentrations were presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL), as assessed by ELISA.

  13. Frequency of gE-specific CD4/CD8 T-cells Expressing at Least Two Different Activation Markers

    Time frame: At Months 12, 24 and 36

    Among the activation markers expressed were interleukin-2 [IL-2] and/or interferon-gamma [IFN-γ] and/or tumour necrosis factor-alpha [TNF-α] and/or cluster of differentiation 40-ligand [CD40-L]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS). Month 12, 24 and 36 CMI analyses on CD8+ T cells were not performed as no detectable CD8 T+ cell response was measured to any of the vaccine formulations in the primary (108494) study.

  14. Frequency of gE-specific CD4/CD8 T-cells Expressing IFN-γ and at Least Another Activation Marker

    Time frame: At Months 12, 24 and 36

    Among other activation markers expressed were interleukin-2 [IL-2] or tumour necrosis factor-alpha [TNF-α] or cluster of differentiation 40-ligand [CD40-L]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS). Month 12, 24 and 36 CMI analyses on CD8+ T cells were not performed as no detectable CD8 T+ cell response was measured to any of the vaccine formulations in the primary (108494) study.

  15. Frequency of gE-specific CD4/CD8 T-cells Expressing IL-2 and at Least Another Activation Marker

    Time frame: At Months 12, 24 and 36

    Among other activation markers expressed were interferon-gamma [IFN-γ] or tumour necrosis factor-alpha [TNF-α] or cluster of differentiation 40-ligand [CD40-L]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS). Month 12, 24 and 36 CMI analyses on CD8+ T cells were not performed as no detectable CD8 T+ cell response was measured to any of the vaccine formulations in the primary (108494) study.

  16. Frequency of gE-specific CD4/CD8 T-cells Expressing TNFα and at Least Another Activation Marker

    Time frame: At Month 12, 24 and 36

    Among other activation markers expressed were interleukin-2 [IL-2] or interferon-gamma [IFN-γ] or cluster of differentiation 40-ligand [CD40-L]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS). Month 12, 24 and 36 CMI analyses on CD8+ T cells were not performed as no detectable CD8 T+ cell response was measured to any of the vaccine formulations in the primary (108494) study.

  17. Frequency of gE-specific CD4/CD8 T-cells Expressing CD40L and at Least Another Activation Marker

    Time frame: At Month 12, 24 and 36

    Among other activation markers expressed were interleukin-2 [IL-2] or interferon-gamma [IFN-γ] or tumour necrosis factor-alpha [TNF-α] . Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS). Month 12, 24 and 36 CMI analyses on CD8+ T cells were not performed as no detectable CD8 T+ cell response was measured to any of the vaccine formulations in the primary (108494) study.

  18. Anti-gE Specific Antibody Concentrations

    Time frame: At Months 12, 24 and 36

    Concentrations were presented as geometric mean concentrations (GMCs) and expressed in enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).

  19. Anti-varicella Zoster Virus (VZV) Specific Antibody Concentrations

    Time frame: At Months 12, 24 and 36

    Concentrations were presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL).

  20. Frequency of VZV-specific Memory B-cells in a Subset of Subjects

    Time frame: At pre-vaccination (Day 0) and at Month 3

    Memory B cells specific to the gE antigen, as assessed by the enzyme-linked immunosorbent spot (ELISPOT) method, were expressed as a frequency of the specific memory B-cells per million memory B-cells. Results were tabulated for subjects aged 70 years and older.

  21. Number of Subjects With Different Biochemical and Haematological Levels

    Time frame: At Day 0, Month 2 and Month 3

    Among biochemical and haematological parameters assessed were albumin [ALB], alanine aminotransferase [ALT], aspartate aminotransferase [AST], basophils [BAS], calcium [CAL], eosinophils [EOS], fibrinogen [FIB], haematocrit [HEM], hemoglobin [Hgb], leucocytes [LEU], lymphocytes [LYM], lactate dehydrogenate [LDH], monocytes [MON], neutrophils [NEU], partial thromboplastin time [PTPT], platelets [PLA], pro thrombin time [PTT], red blood cells [RBC], serum creatinine [SCREA], total protein [TP]. Levels of haematological/biochemical parameters assessed in terms of normal laboratory values were - unknown, below, within and above.

  22. Number of German Subjects With Different Biochemical and Haematological Levels

    Time frame: At one week post-vaccination 1 (Month 0)

    Among biochemical and haematological parameters assessed were albumin [ALB], calcium [CAL], fibrinogen [FIB], lactate dehydrogenase [LDH], partial thrombo-plastin time [PTPT], pro thrombin time [PTT], total protein [TP]. Levels of haematological/biochemical parameters assessed in terms of normal laboratory values were - below, within, above and missing, as compared to the pre-vaccination status (below, within, above or missing). Values for electrophoresis (globulins and albumin/globulin ratio) were not displayed.

  23. Number of German Subjects With Different Biochemical and Haematological Levels

    Time frame: At one week post-vaccination 2 (Month 2)

    Among biochemical and haematological parameters assessed were albumin [ALB], calcium [CAL], fibrinogen [FIB], lactate dehydrogenase [LDH], partial thrombo-plastin time [PTPT], pro thrombin time [PTT], total protein [TP]. Levels of haematological/biochemical parameters assessed in terms of normal laboratory values were - below, within, above and missing, as compared to the pre-vaccination status (below, within, above or missing). Values for electrophoresis (globulins and albumin/globulin ratio) were not displayed.

  24. Number of Subjects With Any and Grade 3 Solicited Local Symptoms

    Time frame: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses

    Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.

  25. Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms

    Time frame: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses

    Assessed solicited general symptoms were arthralgia, fatigue, fever [defined as oral temperature equal to or above (≥) 37.5 degrees Celsius (°C)], headache and myalgia. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever > 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.

  26. Number of Subjects With Occurrence of Clinically Diagnosed Herpes Zoster (HZ) Episodes

    Time frame: From Month 0 to Month 3

    Clinically diagnosed episodes included rash that was assessed by hives, idiopathic thrombocytopenic purpura, petechiae.

  27. Number of Subjects With Occurrence of Clinically Diagnosed HZ Episodes

    Time frame: From Month 3 up to Month 36

    Clinically diagnosed episodes included rash that was assessed by hives, idiopathic thrombocytopenic purpura, petechiae.

  28. Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)

    Time frame: During the 30-day (Days 0-29) post-vaccination period

    An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.

  29. Number of Subjects With Serious Adverse Events (SAEs)

    Time frame: From Month 0 to Month 3

    Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

  30. Number of Subjects With Serious Adverse Events (SAEs)

    Time frame: From Month 3 to Month 12

    Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

Sponsors and collaborators

Lead sponsor

GlaxoSmithKline

Industry

Registry information

Official study title

A Phase II, Single-blind, Randomized, Controlled, Multicentre Vaccination Study to Evaluate the Safety and Immune Response of the GSK Biologicals Zoster Vaccine, gE/AS01B, and to Compare 3 Doses of gE With AS01B Adjuvant in Healthy Elderly Subjects, Aged 60 to 69 Years and 70 Years and Above.

Important dates

Study start
2007
Primary completion
2007
Study completion
2010
First posted
Feb 13, 2007
Registry last updated
Mar 15, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.